MATILDE疗法辅以放疗是治疗原发性CNS淋巴瘤的有效方案

• 作 者: Ferreri A.J.M. Dell'Oro S Foppoli M. 史利利
• 机 构: Medical Oncology Unit Department of Oncology San Raffaele H Scientific Institute Via Olgettina 60 2
• 出 处: 世界核心医学期刊文摘(神经病学分册)
• 发表日期: 2006年09期
• 关键词: 淋巴瘤 结外淋巴瘤 淋巴瘤患者 化疗疗效 放疗方案 生存曲线 存活率 平台期 骨髓 毒性

The authors assessed MATILDE chemotherapy followed by response-tailored radiation therapy in 41 patients aged 70 years or younger with primary CNS lymphoma in a Phase II trial. With response rates of 76%after MATILDE and 83%after chemotherapy with or without radiation therapy, this was an active strategy, particularly in low-to intermediate-risk patients (International Extranodal Lymphoma Study Group [IELSG]-score). Myelosuppression was the dose-limiting toxicity, with 9.5%of lethal complications. After a median follow-up of 49 months, a plateau in the survival curve (5-year overall survival: 41 ±7%) was obtained.

The authors assessed MATILDE chemotherapy followed by response-tailored radiation therapy in 41 patients aged 70 years or younger with primary CNS lymphoma in a Phase II trial. With response rates of 76% after MATILDE and 83% after chemotherapy with or without radiation therapy, this was an active strategy, particularly in low-to-intermediate-risk patients (International Extranodal Lymphoma Study Group [IELSG] -score). Myelosuppression was the dose-limiting toxicity, with 9.5% of lethal complications. After a median follow-up of 49 months, a plateau in the survival curve (5-year overall survival: 41 ± 7%) was obtained.